Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 25: Vascular Diseases and Diabetic Retinopathy VII Session

Date/Time: | Room:

Back to Previous

Title

Theme

10:00:00 H. Kaldırım Turkey The role of postinjection topical antibiotics prophylaxis on conjunctival bacterial flora and antibiotic resistance patterns after serial intravitreal injections in type 2 diabetic patients
10:06:00 T. Kiseleva Russian Federation Effect of resveratrol on two different experimental models of retinal ischemia/reperfusion in rats
10:12:00 Y. Chen Taiwan The association between retinal vein occlusion and an increased risk of cerebrovascular accident: A 13year populationbased cohort study
10:18:00 O. Sever Turkey The effect of intravitreal aflibercept on neovascular glaucoma in previously vitrectomized patients
10:24:00 H. Yetik Turkey Fellow eye effects of monocular intravitreal bevacizumab (IVB) injection for retinopathy of prematurity (ROP)
10:30:00 M. Nghiem-Buffet France Insights into perifoveal exudative vascular anomalous complex
10:36:00 A. Dale United Kingdom Reduction in blindness rates since the introduction of digital photographic screening in an English diabetic eye screening programme
10:42:00 A. Eaton United States Realworld outcomes in the US following the use of the fluocinolone acetonide (FAc) 0.19 mg (ILUVIEN) implant in patients with diabetic macular edema: The results from the USER Study
10:48:00 S. Liakopoulos Germany Morphological outcomes of the PRIDE study using fluorescein angiography and a modified ETDRS severity scale grading for PDRpatients treated with ranibizumab and/or panretinal photocoagulation (PRP)
10:54:00 E. Alyamac Sukgen Turkey Aflibercept treatment for retinopathy of prematurity
11:00:00 C. Madeira Portugal Prevalence of diabetic retinopathy in diabetes type 1 patients: are the trends changing?
11:06:00 E. Ciloglu Turkey Changes in the macular ganglion cell complex thickness and central macular thickness after antiVEGF treatment for diabetic macular edema

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved